The European Commission has granted unconditional approval for Novo Holdings A/S to acquire Catalent, Inc., with the acquisition expected to close by the end of 2024. Catalent's CEO Alessandro Maselli has welcomed the approval, while Novo Holdings' Senior Partner Jonathan Levy affirmed their commitment to supporting Catalent's future growth. The transaction remains subject to final regulatory clearances and closing conditions.

The following article originally appeared in Business Wire.

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S, a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent.

“We are pleased to have received European Commission approval, which is a significant milestone toward completing our pending transaction with Novo Holdings,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “I am deeply grateful for the ongoing commitment and efforts of the Catalent team. There is tremendous positive momentum underway at Catalent, and I believe that our future is even brighter as a private company with the support of Novo Holdings.”

“With the European Commission’s approval, we are one step closer to delivering the benefits of this transaction,” said Jonathan Levy, Senior Partner, Novo Holdings. “We look forward to supporting Catalent in its next chapter as it continues to create value for stakeholders, ultimately delivering better outcomes for the Company’s customers and the patients they serve.”

The transaction is expected to close towards the end of calendar year 2024, subject to the satisfaction of other customary closing conditions, including receipt of all requisite regulatory clearances.

For more, please find the original story source here.